Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (November 2021)
46 slides from Immatics's investor presentation, Nov 9, 2021
Slide 1: Unlocking Immunotherapies for Solid Cancer Patients
© Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, November 2021
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of its or their con
Slide 3: Building a leading TCR Therapeutics Company
Building a leading TCR Therapeutics Company with a Pipeline in Cell Therapies and Bispecifics 3 Highly Differentiated Technologies to Identify True Cancer Targets and the Right TCRs Unlocking Immunotherapies for Solid Cancer Patients Strategic Collaborations with World - leading Industry Players
Slide 4: Limitations of Current Immunotherapies in Solid Cancer Patients
Limitations of Current Immunotherapies in Solid Cancer Patients … Driven by a Lack of Known Cancer - specific Targets 4 1 Chalmers et al. , 2017; 2 SEER Cancer Statistics Review, 1975 - 2017, Estimated New Cancer Cases for 2020 Checkpoint inhibitors mainly effective in tumors with high mutational bu
Slide 5: Immatics Pipeline
Immatics Pipeline 5 Modality Product Candidate Status Preclinical Phase 1a 1 Phase 1b 1 Phase 2/3 ACTengine® Autologous ACT IMA201 (MAGEA4/8) Proprietary IMA202 (MAGEA1) Proprietary IMA203 (PRAME) Proprietary IMA203 (PRAME) + Checkpoint Inhibitor Proprietary IMA203CD8 (PRAME) Proprietary IMA204 (COL
Slide 6: Selected solid cancer indications with target prevalence
IMA201 / IMA401 IMA202 IMA203 / IMA402 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Selected solid cancer indications with significant target prevalence 1 Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovari
Slide 7: ACTengine Programs – Key Features
ACTengine® Programs – Key Features 7 1 Applying XPRESIDENT® quantitative mass spectrometry platform; target density: p eptide copy number per tumor cell, approximate range representing the majority of tumor samples analyzed; 2 Applying XCEPTOR® TCR discovery and engineering platform incl. XPRESIDENT
Slide 8: ACTengine IMA203 – TCR-T to PRAME
ACTengine ® IMA203 – TCR - T to PRAME 8
Slide 9: ACTengine IMA203 to PRAME – Mechanism of Action
ACTengine ® IMA203 to PRAME – Mechanism of Action Immatics’ Leading TCR - T Approach 9
Slide 10: ACTengine IMA203 – Patient Flow
ACTengine® IMA203 – Patient Flow 10 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase ACTengine ® Manufacturing by Immatics Infusion of ACTengine® T cell Product Lymphodepletion 30 mg/m 2 Flu darabine 1 and 500 mg/m 2 Cy
Slide 11: ACTengine IMA203 – Key Objectives & Trial Design
ACTengine® IMA203 – Key Objectives & Trial Design Trial Design & Recruitment Status 1 Enrichment cohorts EC1 & EC2: patients infused with intermediate doses enabling infusion of patients with medical need during do se escalation observation periods, or in case of lower production yields; * One patie
Slide 12: ACTengine IMA203 – Safety Profile
ACTengine® IMA203 – Safety Profile Manageable & Transient Treatment - emergent Adverse Event s – No ≥ Grade 3 CRS or ICANS Adverse event All grades ≥ Grade 3 No . % No . % Patients with any adverse event 19 100.0 19 100.0 Adverse Events of Special interest Cytokine release syndrome 1 7 8 9.5 0 0.0 I
Slide 13: ACTengine IMA203 – Change in Target Lesions
ACTengine ® IMA203 – Change in Target Lesions Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells 1 RECIST1.1 response at the timepoint of maximum change of target lesions (week 12): PD due to new lesions ( leptomeningeal disease) at week 12 2 Patients dosed wit
Slide 14: ACTengine IMA203 – Response Over Time
Patient ID Indication Dose 203 - DL1 - 01 Head & Neck Cancer DL1 203 - DL1 - 02 Head & Neck Cancer DL1 203 - DL1 - 03 Ovarian Cancer DL1 203 - EC1 - 01 Melanoma EC1 203 - EC1 - 02 Melanoma EC1 203 - EC1 - 03 Uveal Melanoma EC1 203 - DL2 - 01 Synovial Sarcoma DL2 203 - DL2 - 02 Synovial Sarcoma DL2 2
Slide 15: IMA203 – Engraftment, Persistence & Tumor Infiltration
ACTengine® IMA203 – Engraftment, Persistence & Tumor Infiltration Clinical Responses Consistent with Biological Data T cell Engraftment & Persistence Tumor Infiltration post I nfusion 2 1 Mann - Whitney U test, p=0.065 ; 2 Post infusion biopsies at week 6 (except one patient with SD at week 3); 3 Ma
Slide 16: IMA203 – Case Study Patient IMA203-DL3
ACTengine ® IMA203 – Case Study Patient IMA203 - DL3 - 01 Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions Liver metastasis Lung metastasis Sub cut . metastasis 0 5 10 15 -100 -50 0 50 Weeks from T Cell Infusion C h a n g e i n D i a m e t e r f r o m B a s e l i n e [
Slide 17: IMA203 PRAME – Phase 1a Dose Escalation Interim Update
ACTengine® IMA203 PRAME – Phase 1a Dose Escalation Interim Update Objective responses observed across multiple tumor types at dose levels below 1 billion T cells originally presumed to be subtherapeutic 1 DLT: dose - limiting toxicity, since March 17, 2021 (reported DLT at DL2); 2 CRS: cytokine rele
Slide 18: Comprehensive Strategy to Target PRAME
Comprehensive Strategy to Target PRAME 18
Slide 19: Immatics' Proprietary PRAME Peptide-HLA/TCR Pair
Immatics’ Proprietary PRAME Peptide - HLA/TCR Pair Broadly Expressed Target on Multiple Solid Cancers Combined with Highly Specific TCR Uterine carcinoma SqNSCLC Melanoma Ovarian carcinoma HNSCC Uveal melanoma 2 Peptide Target PRAME: • HLA - A*02 - restricted peptide identified by XPRESIDENT® quant.
Slide 20: Comprehensive Strategy to Target PRAME
Targeted 2022 Comprehensive Strategy to Target PRAME Phase 1b Cohort A: IMA203 Monotherapy in Focus Indications Phase 1b Cohort B: IMA203/Checkpoint Inhibitor Combination Therapy Phase 1b Cohort C: IMA203CD8 2nd gen Monotherapy Phase 1a: IMA203 Monotherapy Dose Escalation in Basket Trial TCR - T Tra
Slide 21: ACTengine IMA203CD8 – Second-generation TCR-T
ACTengine® IMA203CD8 – Second - generation TCR - T Building on First - Gen IMA203 Success to Further Improve Anti - Tumor Activity • Engagement of CD4 T cells by CD8 co - transduction reported to boost anti - tumor activity in TCR - T trials • Functional superiority of a CD8 αβ IMA203 construct (IMA
Slide 22: IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy
ACTengine® IMA203CD8 – Preclinical Assessment of Anti - Tumor Efficacy Co - Transduction of CD8 Enhances Anti - Tumor Activity in Vitro 18 36 56 74 94 114134 152 172192 0.0 0.5 1.0 1.5 2.0 IMA203CD8 TCR IMA203 TCR Non - Transduced Control S erial Killing Assay – CD8 & CD4 T cells Engagement of CD4 T
Slide 23: Comprehensive Strategy to Target PRAME
Comprehensive Strategy to Target PRAME Focused and broad approach targeting PRAME: Aiming to maximize clinical benefit through ACT programs and TCR Bispecifics • Complete IMA203 Ph1a Dose Escalation with doses above 1 bn cells (DL4) • D etermine Recommended Phase 2 Dose (RP2D) in 1Q2022 • Initiate I
Slide 24: ACTengine TCR-T Programs Update
ACTengine ® IMA 200 TCR - T Programs Update 24
Slide 25: ACTengine Programs – Status Update
ACTengine ® Programs – Status Update 25 1 One DLT in DL2 previously reported in March 2021, fully resolved ACT IMA201 IMA202 IMA203 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Status Dose escalation ongoing Enrollment at target dose level (DL3) ongoing Enrollment at target dose level (DL4) ongoing IN
Slide 26: Unlocking Immunotherapies for Solid Cancer Patients: IMA203 PRAME
Unlocking Immunotherapies for Solid Cancer Patients IMA203 - PRAME Objective responses observed across multiple tumor types 26 82% Disease Control Rate 0 Grade ≥3 CRS or ICANS 1 <1bn T cells infused in almost all patients PRAME STRATEGY Maximizing the therapeutic potential of targeting PRAME ORR 2 a
Slide 27: ACTengine IMA204 – Novel TCR-T Targeting Tumor Stroma
ACTengine ® IMA204 – A Novel TCR - T Program Targeting Tumor Stroma Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 1 In vivo data by Jim Riley, University of Penn
Slide 28: Outlook: ACTallo IMA301 – Allogeneic Cell Therapy Approach
Outlook: ACTallo ® IMA301 – Immatics’ Allogeneic Cell Therapy Approach Effective Redirection of γδ T cells Using αβ TCR 28 • Proprietary manufacturing protocol delivering robust expansion of γδ T cells with the potential for hundreds of doses from one single donor leukapheresis • Off - the - shelf c
Slide 29: TCER – TCR Bispecifics
aoe Immatics TCER® — TCR Bispecifics
Slide 30: TCER – Mechanism of Action
TCER® – Mechanism of Action Immatics ´ Off - the - Shelf TCR Bispecifics Approach 30 TCER®
Slide 31: TCER – Half-Life Extended Bispecifics
TCER® – Immatics’ Innovative Half - Life Extended Bispecifics 31 pHLA targeting TCR x High - affinity TCR with broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 2 x Targets HLA - A*02 - restricted MAGEA4/8 (IMA401) or PRAME (IMA402) peptide with high target density x
Slide 32: TCER Portfolio
TCER® Portfolio TCER Pipeline Strengthened by a Third Program IMA40X 32 IMA401 IMA402 IMA40X MAGEA4/8 PRAME Undisclosed Status CTA filing in Germany targeted Q4 2021 Phase 1 trial in 2022 Clinical GMP batch targeted in 2022 Phase 1 trial in 2023 TCER ® engineering and preclinical testing ongoing Pre
Slide 33: TCER IMA401 Targeting MAGEA4/8
33 Treatment schedule Tumor Model in Mice 1 1 8 15 22 Study day Transplantation Human PBMC IMA401 TCER ® Transplantation Tumor -22-12 TCER® IMA401 Targeting MAGEA4/8 Highly Potent Biologic Leading to Tumor Eradication at Low Concentrations • Complete remissions observed in all animals even at low IM
Slide 34: TCER IMA402 Targeting PRAME
34 TCER® IMA402 Targeting PRAME Superior Anti - Tumor Activity of IMA402 Low - Affinity Recruiter at Low Doses Widely used T cell recruiting Ab (3 variants) medium to high affinity Treatment schedule N=6 mice per group, two PBMC donors Dose: 0.025 mg/kg Proprietary, low - affinity T cell recruiting
Slide 35: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics‘ Proprietary Target and TCR Dicovery Platforms 35
Slide 36: Accessing Intracellular Cancer Targets with TCR-based Therapeutics
Accessing Intracellular Cancer Targets with TCR - based Therapeutics To Unlock Immunotherapies for Solid Cancer Patients 36 Technology
Slide 37: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs 37 True Targets - expressed on cancer but not or to far lower extent on normal tissue Minimizing risk for on - target toxicity Right TCRs - highly specific and high affinity as outcome of stringent development process Minimizing risk for off - target toxicit
Slide 38: XPRESIDENT – Discovery of True Cancer Targets
XPRESIDENT® – Discovery of True Cancer Targets Pool of 200 Targets as Foundation for our Future Pipeline >2,500 cancer & normal tissues a nalyzed by Quantitative, Ultra - Sensitive Mass Spectrometry pHLA Database based on primary tissues >200 prioritized targets Technology 38 200 Prioritized Targets
Slide 39: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 39 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo ® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Protein engi
Slide 40: Corporate Information & Milestones
Corporate Information & Milestones 40
Slide 41: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage 41 • >8,000 cancer targets, TCRs and technology protected by • 5,500 applications and patents filed in all major countries and regions • >120 patent families • >1,550 granted patents, thereof >450 granted patents in the US Corporate
Slide 42: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 42 Senior Leadership, Business Development, Clinical Operations, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Aff
Slide 43: Experienced Global Leadership Team Across Europe and the US
Experienced Global Leadership Team Across Europe and the US 43 Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience ( Micromet , Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs pha
Slide 44: Upcoming R&D Milestones
Upcoming R&D Milestones 44 Modality Product Candidate Status Preclinical Phase 1a 1 Phase 1b 1 Phase 2/3 Next Milestone ACTengine® Autologous ACT IMA201 (MAGEA4/8) Proprietary Complete dose escalation 2022 IMA202 (MAGEA1) Proprietary Complete dose escalation 1Q2022 IMA203 (PRAME) Proprietary Complet
Slide 45: Immatics Key Take-Aways
Immatics Key Take - Aways Broadly Positioned in the TCR Therapeutics Space with ACT & TCR Bispecifics ACTengine ® (TCR - T) – High Objective Response Rate during ongoing dose escalation in TCR - T Ph1a trial IMA203 to PRAME • IMA203 (PRAME): Objective responses across multiple tumor types at dose le
Slide 46: Thank you
8oe immiatics yr DELIVERING THE POWER \ OF T CELLS TO CANCER PATIENTS j 7 ate F | Thank you ‘www.immatics.com in| ¥